간행물

생화학분자생물학회입니다.


BmB Reports

Perspectives of immune checkpoint ligand expression : regulation and clinical implication

  • 작성자

    Sang-Jun Ha
  • 작성일자

    2021-07-15
  • 조회수

    16
Name: Sang-Jun Ha ( sjha@yonsei.ac.kr )
2019-present Affiliate Faculty, POSTECH
2019-present Professor, Yonsei University
2014-2019 Associate Professor, Yonsei University
2009-2014 Assistant Professor, Yonsei University
2007-2009 Research Associate, Emory University School of Medicine, USA
2004-2007 Postdoctoral fellow, Emory University School of Medicine, USA
2001-2004 Postdoctoral fellow, POSTECH
1998-2001 Ph.D., Division of Molecular and Life Sciences, POSTECH

Perspectives of immune checkpoint ligand expression
: regulation and clinical implication

In tumor microenvironment, expression of immune checkpoint ligands (ICLs) is prerequisite to trigger the inhibitory signal via immune checkpoint receptors (ICRs). Although ICL expression frequently occurs in tumor cell-intrinsic manner, extrinsic factors derived from tumor microenvironment can fine-tune ICL expression by tumor cells or prompt non-tumor cells, including immune cells, to express ICLs. Considering extensive interaction between T cells and other immune cells within tumor microenvironment, ICL expression on immune cells can be as significant as ICLs on tumor cells in anti-tumor immune responses. Here we introduce factors, which contribute to induction of ICLs in either tumor cells or immune cells, and concise mechanisms relevant to their induction.


BMB Rep 2021 Jun 3;5347. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34078531/